Imfinzi/treme­li­mum­ab com­bo scores As­traZeneca an­oth­er OS win — this time in liv­er can­cer

Is the tide turn­ing on As­traZeneca’s bat­tered PD-L1/CT­LA4 com­bo?

A sin­gle prim­ing dose of the ex­per­i­men­tal treme­li­mum­ab, fol­lowed by Imfinzi every four weeks, beat Nex­avar (so­rafenib) in help­ing a group of liv­er can­cer pa­tients live longer in a Phase III study, the com­pa­ny re­port­ed, meet­ing the pri­ma­ry end­point.

Specif­i­cal­ly, the two drugs ex­tend­ed over­all sur­vival for pa­tients with un­re­sectable he­pa­to­cel­lu­lar car­ci­no­ma who had not re­ceived pri­or sys­temic ther­a­py and were not el­i­gi­ble for lo­cal­ized treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER